AEON Biopharma Inc. announced recent milestones in the development of ABP-450, a biosimilar candidate to BOTOX®, aimed at achieving full-label U.S. market entry across all therapeutic indications. The company reported positive biosimilarity data in November 2025, supporting its scientific approach and readiness for regulatory engagement. AEON secured $6 million in PIPE financing with the potential for over $7 million in additional capital through warrant exercises, and reached an agreement with Daewoong for note conversion that could provide more than $8 million in potential warrant proceeds. The company's product is already authorized in 69 countries, including FDA approval in the U.S. for aesthetics under the brand Jeuveau®. AEON's next steps include an FDA Type 2a meeting scheduled for January 2026 to align on the analytical pathway for ABP-450 biosimilar development. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.